Regulus Therapeutics' stock set to fall after FDA places hepatitis C treatment on hold

Shares of Regulus Therapeutics Inc. /zigman2/quotes/202916513/composite RGLS +0.78% were set to sell off in after-hours trade Monday, after the biopharmaceutical company said the Food and Drug Administration placed its investigational new drug for the treatment of chronic hepatitis C virus infection on clinical hold. The stock was halted for news, and is scheduled to being trading again at 4:40 p.m. ET. Regulus said the FDA initiated the clinical hold after a second serious adverse event of jaundice was reported. Regulus said it expects to receive a formal letter from the FDA within 30 day, and plans to work with the FDA as it seeks a release of the clinical hold. The stock had plunged 43% year to date through Monday, while the SPDR S&P Biotech ETF /zigman2/quotes/205950134/composite XBI -1.48% has lost 29% and the S&P 500 has slipped 2.1%.

/zigman2/quotes/202916513/composite

Add to watchlist RGLS

Regulus Therapeutics Inc.

US : U.S.: Nasdaq

$ 1.29

+0.01 +0.78%

Volume: 25,632

Sept. 25, 2023 4:00p

P/E Ratio

N/A

Dividend Yield

N/A

Market Cap

$24.94 million

Rev. per Employee

N/A

/zigman2/quotes/205950134/composite

Add to watchlist XBI

SPDR S&P Biotech ETF

US : U.S.: NYSE Arca

$ 71.88

-1.08 -1.48%

Volume: 7.22M

Sept. 25, 2023 4:00p